News | October 16, 2007

CMS Receives FDA Clearance for IMRT Planning Platform

October 17, 2007 – CMS has received FDA 510(k) clearance for Monaco, its next-generation IMRT planning platform reportedly featuring innovative biological cost functions, allowing CMS to begin distributing Monaco for clinical use in the U.S.

Monaco includes multicriterial constrained optimization, a powerful leaf sequencer and a robust Monte Carlo dose calculation algorithm. Monaco is fully integrated with CMS's Focal platform, aiming to provide seamless connectivity and integration with Focal's advanced fusion, contouring, simulation and plan review capabilities.

For more information: www.cms-euro.com

Related Content

IBA Completes Installation of Two Proteus One Proton Therapy Systems in Japan
News | Proton Therapy | July 30, 2018
IBA (Ion Beam Applications S.A.) announced that they completed the first two installations of the Proteus One proton...
​ITN Celebrates World Cancer Day 2018
News | Radiation Oncology | February 01, 2018
World Cancer Day takes place annually on Feb.
UZ Leuven Treats First European Patient on Varian Halcyon Cancer Treatment System
News | Intensity Modulated Radiation Therapy (IMRT) | October 25, 2017
Varian recently announced an 80-year-old male with head and neck cancer became the first patient in Europe to be...
Varian Receives FDA 510k Clearance for Halcyon Treatment System
Technology | Intensity Modulated Radiation Therapy (IMRT) | July 05, 2017
Varian Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Halcyon system,...
First New York Metropolitan Hospital Treats Cancer Patients With Accuray Radixact System
News | Image Guided Radiation Therapy (IGRT) | July 03, 2017
Accuray Inc. and Montefiore Einstein Center for Cancer Care (MECCC), part of the Montefiore Health System (MHS),...
IUCT Oncopole Installs First Radixact Radiotherapy System in France
News | Intensity Modulated Radiation Therapy (IMRT) | June 20, 2017
Accuray Inc. announced that the University Cancer Institute of Toulouse Oncopole (IUCT Oncopole) in Toulouse, France,...
cervical and endometrial cancer, IMRT, intensity modulated radiation therapy, side effects, ASTRO 2016 study
News | Intensity Modulated Radiation Therapy (IMRT) | September 29, 2016
Patients with cervical and endometrial cancer have fewer gastrointestinal and genitourinary side effects and experience...
non-small cell lung cancer, NSCLC, IMRT, toxicity, intensity modulated radiation therapy, 3-D CRT, ASTRO 2015
News | Lung Cancer | October 28, 2015
October 28, 2015 — An analysis of an international, cooperative-led trial of patients with locally advanced non-small
Overlay Init